Dr. Stone Discusses Monitoring Mrd In Aml

Dr. Stone Discusses Monitoring MRD in AML

Prof. Richard Stone | EBMT 2018 | Latest advances in monitoring MRD in AML

Dr. Stone on Monitoring Patients With AML

Monitoring MRD in Patients with AML

Targeted Oncology

The importance of MRD monitoring in AML

VJHemOnc – Video Journal of Hematology & HemOnc

Updates on the use of molecular monitoring to detect MRD in AML

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Stone on MRD in Hematologic Malignancies

Methods to evaluate MRD in AML

VJHemOnc – Video Journal of Hematology & HemOnc

The importance of MRD in AML prognosis and therapy

VJHemOnc – Video Journal of Hematology & HemOnc

An insight into MRD monitoring and MRD-driven treatment in AML

VJHemOnc – Video Journal of Hematology & HemOnc

Minimal residual disease (MRD) as a prognostic factor for acute myeloid leukemia (AML)

VJHemOnc – Video Journal of Hematology & HemOnc

Molecular diagnosis and MRD monitoring in AML

VJHemOnc – Video Journal of Hematology & HemOnc

The prognostic and therapeutic implications of MRD in AML

VJHemOnc – Video Journal of Hematology & HemOnc

The role of MRD monitoring using MFC for AML: a real-world study

VJHemOnc – Video Journal of Hematology & HemOnc

Dr Richard Stone discusses the results of the CALGB 10603/RATIFY study

MRD to determine risk of relapse after induction in AML

VJHemOnc – Video Journal of Hematology & HemOnc

The current role of MRD in AML and challenges with implementing this in clinical practice

VJHemOnc – Video Journal of Hematology & HemOnc

MRD detection techniques in AML: pros and cons

VJHemOnc – Video Journal of Hematology & HemOnc

MRD Monitoring in Acute Myeloid Leukemia

Is MRD monitoring prior to allograft standard in AML?

VJHemOnc – Video Journal of Hematology & HemOnc